ストックスクリーナーアプリを入手
32.84
0.61%
-0.20
プレマーケット:
32.74
-0.10
-0.30%
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Uncovering a 53.98% Potential Upside in Biotech - DirectorsTalk Interviews
What is HC Wainwright's Forecast for MLYS FY2030 Earnings? - MarketBeat
Insider Trends: How sensitive is Mineralys Therapeutics Inc to inflationWeekly Trade Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Aug EndMonth: Will CMPS benefit from rate cutsJuly 2025 Pullbacks & AI Powered Market Entry Ideas - baoquankhu1.vn
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (MLYS) Movement - Stock Traders Daily
Mineralys Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
Relative Strength Alert For Mineralys Therapeutics - Nasdaq
Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com
Rodman sells Mineralys (MLYS) shares for $13,353 By Investing.com - Investing.com Nigeria
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Fed Watch: What is Mineralys Therapeutics Incs revenue forecast2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Activity Recap: Is EKSO a potential multi baggerAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Are Mineralys Therapeutics’ (MLYS) Executive Stock Plans Aligned With Lorundrostat’s Emerging Investment Story? - Sahm
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock - MarketBeat
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Sell Signal: Is Mineralys Therapeutics Inc. part of any major index2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Mineralys Therapeutics MLYS officer sells $277k in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock By Investing.com - Investing.com Canada
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com
Mineralys Therapeutics MLYS officer sells $277k in stock - Investing.com
Buybacks Report: Will Mineralys Therapeutics Inc outperform tech stocksQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Patterns Watch: Whats Mineralys Therapeutics Incs historical returnJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Unveiling a 54% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Discipline and Rules-Based Execution in MLYS Response - Stock Traders Daily
Trend Recap: Whats the RSI of Mineralys Therapeutics Inc stockJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Will Mineralys Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Outlook & Risk Adjusted Buy/Sell Alerts - Улправда
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga España
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsEarnings Risk Summary & Weekly Breakout Watchlists - ulpravda.ru
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 7%Here's What Happened - MarketBeat
Is Mineralys Therapeutics Inc. stock a contrarian buyJuly 2025 Breakouts & Verified Momentum Watchlists - Улправда
Why Mineralys Therapeutics Inc. stock could outperform in 2025Quarterly Growth Report & Free Fast Entry Momentum Trade Alerts - Улправда
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision - mychesco.com
Mineralys Therapeutics, Inc.Common Stock (NQ: MLYS - FinancialContent
Mineralys Therapeutics Insider Sold Shares Worth $9,261,028, According to a Recent SEC Filing - marketscreener.com
MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 70,037 Shares of Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $6,748,879.30 in Stock - MarketBeat
Mineralys Therapeutics CMO Sells Over $9 Million in Company Stock - TradingView — Track All Markets
Mineralys Therapeutics(MLYS.US) Officer Sells US$9.26 Million in Common Stock - 富途牛牛
Mineralys Therapeutics: Lorundrostat’s Broad Efficacy, Favorable Safety, and Upside Indications Support Buy Rating on MLYS - TipRanks
Mineralys Therapeutics filed NDA for lorundrostat to U.S. FDA in late 2025 - marketscreener.com
Mineralys updates lorundrostat program and upcoming data milestones - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Analyzing a Potential 42.67% Upside in the Biotech Sector - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. Provides Corporate Update and Announces NDA Filing - TradingView — Track All Markets
Mineralys Therapeutics Provides Corporate Update and - GlobeNewswire
Will Mineralys Therapeutics Inc. stock maintain dividend yield2026 world cup usa national team round of 32 midfield engines build up play match prediction statistical analysis - Улправда
Is JAMA-Lauded Launch-HTN And FDA Feedback Altering The Investment Case For Mineralys Therapeutics (MLYS)? - Sahm
Is Mineralys Therapeutics Getting To The Heart Of Hypertension With Lorundrostat? - RTTNews
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):